Sustained Delivery prolongs the release of a therapeutic which can result in increased exposure and potency of a given target molecule. Advances in the design of biomaterials, such as hydrogels, microspheres, implants and nanoparticles, have contributed to the precise delivery of this therapeutic modality revolutionizing how patients are treated for many acute and chronic conditions.
Genie Biotech’s proprietary conjugation technology allows Researchers to fine tune a drug’s release in a highly controlled, novel manner. Not only are target molecules site-specifically bound to a matrix of your choosing, but the conjugate bond can also be tuned to reverse thus releasing the native molecule.
MECHANISM
Target molecules can be rapidly installed on a selected matrix under mild conditions, preserving the biological function of your therapeutic.
You can then fine tune the reversibility by controlling the rate at which the conjugate bond hydrolyzes to release your native biologic from the matrix.
1) Using FDA approved additives
2) Modifying N-terminal sequence
Our Locations
Genie Biotech Ltd.
St.Saviour
Jersey
JE2 7LA, UK
Tel: +44 (0) 1409 331154
UAB Genie Biotech EU
Santariškių g. 5,
Vilnius
08406, Lithuania
Tel: +37 (0) 52144617
Products & Services
Applications
Events
Upcoming Events:
BIO International Convention 2024: San Diego
3rd June 2024 – 6th June 2024
Previous Events:
BIO International Convention 2023: Boston
5th June 2023 – 8th June 2023